Abstract IA07: Addiction of prostate cancer to androgen receptor

Abstract

Abstract Recurrence with lethal castration-resistant prostate cancer after endocrine therapy remains the major challenge in treatment of advanced prostate cancer. Significant advances in our understanding of continued androgen receptor signaling in castration-resistant prostate cancer have led to the development and FDA approval of two next-generation endocrine therapy drugs, the androgen biosynthesis inhibitor abiraterone and the potent androgen receptor antagonist enzalutamide. These drugs heralded a new era of prostate cancer therapy. However, some patients present with therapy-resistant disease, and most initial responders develop acquired resistance within months of therapy initiation. Recent studies indicate that these resistant tumors commonly remain androgen receptor driven. This presentation will describe how the androgen receptor signal pathway evades endocrine therapies and how our understanding of endocrine treatment resistance is providing insights into novel therapeutic strategies for improving outcome from this disease. Citation Format: Yan Dong. Addiction of prostate cancer to androgen receptor. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr IA07.